Search Results

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.

Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, is pleased to announce that the first patient has been treated in Europe with naronapride, a potential best-in-class pan-GI prokinetic, in a Phase IIb trial for gastroparesis conducted by Dr. Falk Pharma GmbH (Dr. Falk Pharma).

FundaMental Pharma GmbH announced the appointment of Dr. Lorenz Mayr to its Board of Directors.

FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal disorders, announced that it has entered into a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH to jointly develop and commercialize Naronapride, a unique late-stage GI prokinetic, initially for gastroparesis.